Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …

Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …

Obesity, exceptionally prevalent in the USA, promotes the incidence and progression of
numerous cancer types including breast cancer. Complex, interacting metabolic and …

Abstract Background The American Cancer Society, Centers for Disease Control and
Prevention, National Cancer Institute, and North American Association of Central Cancer …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

This article is the American Cancer Society's biennial update on female breast cancer
statistics in the United States, including data on incidence, mortality, survival, and screening …

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly
improved survival in several cancer settings. A subgroup of women with breast cancer (BC) …